Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
AOD-9604 is sold for research purposes only and is not FDA-approved for human therapeutic use
IV and short-duration oral trials METAOD001-004 enrolled smaller groups of healthy or obese men with single doses or 1-week dosing across IV (25-400 mcg/kg) and oral (9-54 mg) routes
Special considerations and populations Certain individuals may need protocol modifications based on specific circumstances or characteristics
This finding is particularly noteworthy given that some trials extended to 24 weeks of continuous exposure and included participants with obesity-related comorbidities who might be expected to have higher baseline health risks
Pause for 2-3 seconds after full depression to prevent solution from leaking back out
- how GLP-1/GIP dual agonism compares to direct lipolysis - Retatrutide vs Tirzepatide - the triple agonist achieving 24.2% weight loss - How Does Retatrutide Work
/product/19/3469114/1.jpg?9363)
US$ 29.40
US$ 20.19
US$ 22.35
US$ 29.61
US$ 29.63
US$ 21.09
